Logo image of AELIS.PA

AELIS FARMA SAS (AELIS.PA) Stock Fundamental Analysis

EPA:AELIS - Euronext Paris - Matif - FR0014007ZB4 - Common Stock - Currency: EUR

1.305  -0.02 (-1.14%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AELIS. AELIS was compared to 73 industry peers in the Biotechnology industry. While AELIS seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, AELIS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AELIS had negative earnings in the past year.
In the past year AELIS has reported a negative cash flow from operations.
AELIS had negative earnings in 4 of the past 5 years.
AELIS had negative operating cash flow in 4 of the past 5 years.
AELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFAELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

1.2 Ratios

With a Return On Assets value of -37.83%, AELIS perfoms like the industry average, outperforming 42.47% of the companies in the same industry.
AELIS's Return On Equity of -73.69% is in line compared to the rest of the industry. AELIS outperforms 46.58% of its industry peers.
Industry RankSector Rank
ROA -37.83%
ROE -73.69%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AELIS.PA Yearly ROA, ROE, ROICAELIS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AELIS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AELIS.PA Yearly Profit, Operating, Gross MarginsAELIS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

AELIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
AELIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AELIS.PA Yearly Shares OutstandingAELIS.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
AELIS.PA Yearly Total Debt VS Total AssetsAELIS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

AELIS has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AELIS (0.39) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC7.88%
AELIS.PA Yearly LT Debt VS Equity VS FCFAELIS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

AELIS has a Current Ratio of 3.77. This indicates that AELIS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.77, AELIS is in the better half of the industry, outperforming 68.49% of the companies in the same industry.
AELIS has a Quick Ratio of 3.77. This indicates that AELIS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AELIS (3.77) is better than 71.23% of its industry peers.
Industry RankSector Rank
Current Ratio 3.77
Quick Ratio 3.77
AELIS.PA Yearly Current Assets VS Current LiabilitesAELIS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

AELIS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -41.87%.
Looking at the last year, AELIS shows a very negative growth in Revenue. The Revenue has decreased by -70.42% in the last year.
Measured over the past years, AELIS shows a very negative growth in Revenue. The Revenue has been decreasing by -33.42% on average per year.
EPS 1Y (TTM)-41.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.58%
Revenue 1Y (TTM)-70.42%
Revenue growth 3Y-33.42%
Revenue growth 5YN/A
Sales Q2Q%-91.62%

3.2 Future

The Earnings Per Share is expected to grow by 74.02% on average over the next years. This is a very strong growth
Based on estimates for the next years, AELIS will show a very strong growth in Revenue. The Revenue will grow by 88.24% on average per year.
EPS Next Y-34.44%
EPS Next 2Y7.96%
EPS Next 3Y74.02%
EPS Next 5YN/A
Revenue Next Year-52.86%
Revenue Next 2Y33.1%
Revenue Next 3Y88.24%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AELIS.PA Yearly Revenue VS EstimatesAELIS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
AELIS.PA Yearly EPS VS EstimatesAELIS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 1 -1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AELIS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AELIS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AELIS.PA Price Earnings VS Forward Price EarningsAELIS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AELIS.PA Per share dataAELIS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as AELIS's earnings are expected to grow with 74.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.96%
EPS Next 3Y74.02%

More info and screens

0

5. Dividend

5.1 Amount

AELIS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AELIS FARMA SAS

EPA:AELIS (8/8/2025, 7:00:00 PM)

1.305

-0.02 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.75%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.89M
Analysts84.44
Price Target11.22 (759.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)46.67%
PT rev (3m)46.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.68
P/FCF N/A
P/OCF N/A
P/B 1.77
P/tB 1.8
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0.2
BVpS0.74
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.83%
ROE -73.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.9%
Cap/Sales 7.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.77
Quick Ratio 3.77
Altman-Z N/A
F-Score1
WACC7.88%
ROIC/WACCN/A
Cap/Depr(3y)106.33%
Cap/Depr(5y)205.47%
Cap/Sales(3y)3.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.58%
EPS Next Y-34.44%
EPS Next 2Y7.96%
EPS Next 3Y74.02%
EPS Next 5YN/A
Revenue 1Y (TTM)-70.42%
Revenue growth 3Y-33.42%
Revenue growth 5YN/A
Sales Q2Q%-91.62%
Revenue Next Year-52.86%
Revenue Next 2Y33.1%
Revenue Next 3Y88.24%
Revenue Next 5YN/A
EBIT growth 1Y-19.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-115.71%
EBIT Next 3Y152.58%
EBIT Next 5YN/A
FCF growth 1Y7.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.7%
OCF growth 3YN/A
OCF growth 5YN/A